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TO STUDY THE IMMUNOHISTOCHEMICAL EXPRESSION OF 
BRCA 1 IN BREAST CANCER AND TO ASSESS ITS ASSOCIATION 
WITH EXPRESSION OF ER, PR AND HER 2RECEPTORS 
 
 
Invasive breast cancer in women is a disease of global concern. Overall, 
invasive breast carcinoma is the second most common malignancy next to lung 
cancer. 
 
BRCA 1 gene mutation is one of the commonest causes of hereditary type 
breast carcinoma. BRCA 1 mutation if detected earlier, would improve the 
prognosis of patient in terms of devising a treatment plan that involves 
prophylactic mastectomy as these patients are prone to develop carcinoma sooner 
or later. Therefore mutational studies might help in reducing the rate of incidence 
of breast carcinoma. 
 
Therefore we propose to study the prevalence of BRCA 1 mutation in 
breast carcinoma by Immunohistochemical study, its association with various 
phenotypic features and hormonal receptors 
 
This is a retrospective study. Cases reported as carcinoma breast were 
retrieved from the archives of department of pathology, between the years 2012 
to 2015. H&E, IHC staining with ER, PR,HER 2 is done for the 42 selected 
cases and correlated with each other. 
 
Finally our study on breast carcinoma specimen revealed the incidence is 
around 3.1% of breast cancer among women in our institute. Majority of which 
occurs in the mean age group of 50.5 years. We infer that BRCA 1 mutation was 
seen most in grade 3 / high grade tumors. BRCA 1 mutation was also seen in 
hormone receptor negative cases, in particular estrogen receptors. The limitations 
of our study include small sample size.  A larger prospective study on the utility 
of BRCA 1immunohistochemistry is essential to prove the benefits of this 
mutation analysis for routine treatment and prognostic reasons. 
 
 
KEYWORDS: Breast carcinoma, BRCA 1, ER, PR, HER 2, 
Immunohistochemistry. 
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INTRODUCTION 
Invasive breast cancer in women is a disease of global concern. Overall, 
invasive breast carcinoma is the second most common malignancy next to lung 
cancer.1 
There is an exponential rise in incidence of new breast cancer cases in India 
and also across the globe. The GLOBOCAN project by the INTERNATIONAL 
AGENCY FOR RESEARCH ON CANCER (IARC - WHO) which estimates the 
five year cancer prevalence data found that in the year 2012 around 144,937 cases 
of breast cancer were newly detected in India out of which, 70,128 have died due 
to the cancer itself. In India the ratio between the newly detected cases and death 
rate is approximately two which suggests that one out of every two women die of 
the disease, with ratio 1:2 whereas in China the ratio is 1:4 and in USA the ratio is 
1:6.2 
Moreover the incidence of carcinoma breast affecting young age group is 
on the rise. Recent data’s point to the fact that most of the women with breast 
cancer are diagnosed between the age group 25 to 45years.2  In underdeveloped 
countries and in India majority of the patients present themselves to medical care 
with advanced stages of disease and hence the prognosis is poor leading to poor 
five year survival rate. 
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BRCA 1 gene mutation is one of the commonest causes of hereditary type 
breast carcinoma and the risk of acquiring the disease in this mutation is around 
56% to 90%.3,4  BRCA 1 mutation if detected earlier, would improve the prognosis 
of patient in terms of devising a treatment plan that involves prophylactic 
mastectomy as these patients are prone to develop carcinoma sooner or later. 5 
Therefore mutational studies might help in reducing the rate of incidence of breast 
carcinoma. 
The best known method for detection of BRCA 1 mutation is by molecular 
analysis, which is time consuming and expensive. But now due to the advent of 
Immunohistochemical studies it has become easier to detect the mutation, which is 
cost effective, less cumbersome and results are provided sooner. 
Therefore we propose to study the prevalence of BRCA 1 mutation in 
breast carcinoma by Immunohistochemical study, its association with various 
phenotypic features and hormonal receptors. 
 
 
. 
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AIMS AND OBJECTIVES 
(i) To study the immunohistochemical expression of BRCA1 protein in 
carcinoma breast and 
(ii)  To correlate its expression with the phenotype and receptor status - 
estrogen receptor, progesterone receptor and HER 2 receptor 
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REVIEW OF LITERATURE 
EMBRYOLOGY: 
Breast develops along milk line or mammary ridges that extend from axilla 
to groin. By 5th week of gestation, there occurs thickening of ectoderm in the 
ventral aspect of the embryo forming milk line.6  Normally this line is resolved 
except for a portion, which is remnant over the pectoral area and develops into 
breast. In this region mammary gland develops, at first a thick mass of epidermal 
cells grows downward into the mesenchyme. From this mass 15 to 20 projections 
arise that extends into the mesenchyme. These projections are then canalized. 
Proximal part of the projections is converted into major ducts called lactiferous 
ducts. The terminal portion of the projection proliferates and forms the secretory 
unit which later develops into terminal duct lobular unit. Lactiferous ducts initially 
open into a pit formed by the thickened epidermal cells. As the underlying 
mesenchyme grows it pushes the pit out and forms an elevation above the surface 
which is called the nipple. In women as the age progress these ducts and secretory 
unit undergo drastic changes in particular during puberty and pregnancy.7 
GROSS ANATOMY OF BREAST: 
       There are many factors which influence the size and shape of the breast, these 
includes genetic variations, ethnicity, food habits, age, menstrual status, parity etc. 
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       Anatomical location of the mature breast can be roughly demarcated in 
vertical plane and transverse plane. In vertical plane breast is situated from second 
to sixth portion of rib and in transverse plane from the edge of the sternum along 
its medial side to axillary line which is taken as the lateral extension of breast.8 
       Breast is covered by skin and subcutaneous tissue that overlies deep pectoral 
fascia, the structures that are found beneath this deep pectoral fascia are few 
groups of muscles, located superiorly and inferiorly. Superior muscles are 
pectoralis major and serratus anterior whereas inferior muscle is external oblique. 
A potential space called submammary space which denotes the space developed 
between deep fascia and breast tissue is made up of loose connective tissue which 
allows the breast to be mobile.8 
       Nipple is located roughly corresponding to the fourth intercostal space at the 
centre along midclavicular line. The skin overlying and surrounding the nipple is 
called areola. They contain sweat glands and sebaceous glands that have a direct 
communication with skin externally. These glands function to produce an oily 
secretion which reduces the friction in the nipple areolar complex that is caused 
when the neonate starts to feed. Hence the glands present here appear as an 
elevation surrounding the areola, a characteristic finding in feeding mothers and 
are called as Montgomery tubercles. Owing to the presence of considerable 
amount of melanocytes in the nipple areolar complex, they appear dark in colour.6 
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FUNCTIONAL ANATOMY OF BREAST: 
       Breast is comprised of approximately 15 to 25 lobes.6 These lobes are 
composed of large ducts, its branches and terminal duct lobular units(TDLU). 
TDLU communicates with nipple through larger ducts called lactiferous ducts. A 
lactiferous duct undergoes branching to form segmental duct, segmental duct in 
turn branches into sub segmental ducts and these ducts further divide into smaller 
terminal ducts. Terminal ducts finally end with small acini to form a lobule, called 
as terminal duct lobular unit. Many such terminal duct lobular unit forms one lobe. 
Terminal duct lobular unit is considered to have a secretory function.9 Intervening 
stroma between two lobes is known as interlobular stroma were as stroma in 
between two terminal duct lobular unit is called as intralobularstroma. 
       Breast changes are more evident in the reproductive age group of women and 
also during pregnancy in relation to the changes in the hormonal levels. Estrogen 
and rising progesterone levels during menstruation cause increase in the number of 
acini per lobule. At the time of pregnancy the number and size of lobules increase 
exponentially. Lobules play a critical role in production of colostrums after birth 
and converting into milk. At the time of menopause, these lobules tend to regress 
in size considerably and stroma is converted into radio dense fibrous stroma.1 
Histologically breast tissue is composed of ducts and stroma. The ducts are lined 
by bi-layered epithelium of luminal columnar cells and abluminal myoepithelial 
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cells. Nipple areolar complex and skin covering the breast is lined by keratinizing 
squamous epithelium.  
BREAST CANCER: 
WHO defines invasive breast cancer as a group of malignant epithelial 
tumours which is characterized by invasion into adjacent tissues, lymph nodes and 
increased tendency to metastasize to distant sites. Most of the breast tumors 
belong to the group of adenocarcinoma and tend to arise from the breast 
parenchymal epithelium particularly from that of the terminal duct lobular unit.10 
       Carcinoma breast is the commonest non skin malignant tumor and accounts 
for about 22% of all malignancies in women worldwide. Since the year 2008, 
according to the International Agency for Research on Cancer, the incidence of 
breast cancer has considerably increased about 20% and mortality has increased 
by about 14%.  It estimates that out of every four women affected with cancer one 
tends to have breast cancer.2 
        For the last two decades cancer cervix was the primary cause of death among 
all the cancers in women, in India. However, now breast cancer is considered as 
the most common cause of cancer deaths in women. This is pertaining to the fact 
that in western and other developed countries five year survival rate has been good 
because of early detection of breast cancer due to better awareness about the 
disease and implementation of effective screening programs. Whereas in 
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underdeveloped countries, as well as in India most of the patients present 
themselves to medical care in the terminal stage of the disease where the prognosis 
is poor, hence there is a substantial increase in mortality rate. 
       Incidence curve for breast cancer rises around puberty and peaks at 
menopause and thereafter maintains a steady state.9 The incidence of breast cancer 
affecting young age group is on the rise. Now most of the women with breast 
cancer are diagnosed between the age group 25 – 45years.2 
       According to statistics provided by cancer institute (W.I.A), Chennai between 
the year 2006 and 2008 breast cancer accounts for about 26.3% of all cancers in 
females. This shows the heavy burden of disease within a regional population.11 
 
EPIDEMIOLOGY: 
       Breast cancer is regarded as a disease of affluent society denoting to the fact 
that modified lifestyle leads to intake of high caloric diet and less amount of 
physical activity, as both are considered a major risk factor for the disease.11 
1. RACE: 
       It varies markedly with different ethnic groups because each group may have 
subtle variations in the breast cancer genes leading to the difference in incidence 
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for each country. As example BRCA 1 and BRCA 2 mutations are most common 
among the Jews.12 
2. AGE GROUP: 
       Earlier it was said breast cancer was disease of old, but recent trends show 
that the common age group being affected are from 25-45 years of age.2 
3. MENSTURAL AND REPRODUCTIVE HISTORY: 
       Early menarche, less than 11 years of age and late menopause is viewed as a 
risk factor for breast cancer. Delivering first child at full term around the age of 20 
years generally declines the risk of obtaining breast cancer by 50% than that of 
women who were nulliparous or who delivers their first child at an age of 30 years 
or more.13 
4. ROLE OF ESTROGEN: 
       Increased levels of estrogen is one of the most important concerning factor in 
breast cancer, mostly in the form of post menopausal hormone treatment which is 
an exogenous form of estrogen administration and majority of the breast 
carcinoma cases detected are estrogen receptor positive.14 The national toxicology 
program, in year 2002 declared estrogen a carcinogenic agent. Endogenous 
production of estrogen can be reduced by doing oophorectomy which tends to 
reduce the risk of acquiring breast cancer by 75%.1 
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5. NUTRITION: 
      High caloric intake is deemed to be an important risk factor for causing breast 
cancer. Intake of red meat, alcohol is associated with increased risk. Good amount 
of physical exercise offers some protection against breast cancer in post 
menopausal women as they prevent obesity which can cause insulin resistance. 
Elevated insulin level causes increase in androgen which is then converted into 
estrogen in the adipose tissue thereby causing breast cancer.1 
6. DENSITY OF BREAST: 
       The density of the breast detected by mammogram helps in stratification of 
individuals with higher risk factors; those with high density have 4 to 6 times1 
increased risk of either estrogen receptor positive or negative breast cancer as than 
that of those with low densities. 
7. RADIATION AND ENVIRONMENT: 
       Exposure to radiation in the form of therapy or accidental nuclear radiation, 
leads to an increased rate of breast cancer. Particularly women exposed to 
radiation at early years of age tend to develop breast cancer because breast is in 
the development phase at this age group.15 contamination of surrounding 
environment withy organophosphorous compounds is also considered as a risk 
factor for carcinoma breast because it can exhibit an estrogenic effect on humans.1  
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8. LACTATION: 
      Breast feeding reduces the risk of breast cancer when the duration of feeding is 
prolonged more than the recommended exclusive six months of breastfeeding. 
9. MUTATION: 
       Tumour suppressor genes play a central role in suppressing the tumour 
development as far as any tumor is concerned. A specific type of mutation called 
germ line mutation interfere with the normal functioning of the tumour suppressor 
genes in breast leading to cancer.16 Around 90% of women have a risk of 
developing breast cancer during her lifetime if she was detected to have germline 
mutation.1 
10. BREAST CANCER IN FAMILY: 
       When a woman is found to have breast cancer there is a possibility of about 
15-20%1, that her first degree relatives might have been affected by breast cancer. 
Highlighting fact is that these individuals do not carry any germline mutations as 
stated above but the surrounding environmental factors influence the genes that 
are considered to be low risk for causing breast cancer. Risk is reckoned to be 
minimal if only mother is the closest relative suffering from breast cancer and it is 
detected only after her menopause. 
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PATHOGENESIS: 
       Breast cancers are generally adenocarcinomas and can be further sub 
categorized into three types based upon the expression of estrogen and HER2 
receptors as, estrogen receptor negative - HER 2 receptor negative; estrogen 
receptor positive - HER 2 receptor negative; estrogen receptor positive/negative - 
HER 2 receptor positive.1 This subcategorization is helpful for clinicians in 
formulating treatment protocols and thus influencing prognosis. Carcinoma breast 
in most of the elderly women are positive for estrogen receptor and HER2 
receptor; whereas in young women 50% of the cases are found to be estrogen 
receptor negative.1 
       Cells undergo genetic abnormality when there is an interaction between risk 
factors, environment and genes that are susceptible, these abnormal cells with 
chromosomal alterations were cloned and it undergoes proliferation forming a 
tumor, which is a basic phenomenon of almost all the cancers in human. Causes of 
breast cancer can be either of two types: 
1.    Hereditary / Familial breast cancer  
2.    Sporadic breast cancer 
1.  HEREDITARY BREAST CANCER / FAMILIAL BREAST CANCER: 
       When the genes that are predisposed to cause breast cancer are inherited then 
it is termed familial / hereditary breast cancer. It makes up about 5-10% of all the 
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breast cancer cases.17  Risk is increased by several folds when the close first 
degree relatives are affected like mother, sister. 
       Few important susceptible genes that were identified as cause to breast cancer 
are TP53, BRCA1, BRCA2 and CHEK2. The normal function of these tumour 
suppressor genes are to check cell proliferation and prevent tumour formation by 
repairing the defective DNA and maintaining genomic stability. These tumour 
suppressor genes when mutated will lose their normal function and keeps on 
accumulating the defective gene which leads to development of cancer. 
      Approximately one tenth of breast cancers can be attributable to familial cause, 
out of which our gene of study BRCA 1 and also BRCA 2 accounts approximately 
90%.18  Individuals with BRCA 1 gene mutation are also prone to develop ovarian 
carcinoma (10-20%), epithelial cancers of the prostate and pancreas.1 
2. SPORADIC MUTATION BREAST CANCER: 
The above mentioned risk factors when combined together can cause 
sporadic mutation resulting in breast cancer. Out of all the risk factors the most 
significant one is hormone excess, particularly estrogen. Women are generally 
exposed to excess of hormones in the form of post menopausal hormonal therapy, 
as a contraceptive or as a part of treatment for dysfunctional uterine bleeding. The 
number of menstrual cycles attained by a woman in her years has a higher risk of 
acquiring mutation leading to breast carcinoma. It is due to the fact that during the 
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menstrual cycle there is an increase in breast epithelial growth. Whenever there is 
proliferation there is a high chance of damage to DNA which results in 
accumulation of these damaged DNA. Normally the DNA repair mechanism 
intervenes to correct the damaged DNA at the end of the menstrual cycle. 
However, if the repair mechanism fails the mutated DNA tends to settle in the 
genome. So this is a cyclical process starting from the age of puberty to 
menopause. Therefore each cycle will have an additive effect of the above 
mentioned mechanism leading to increased risk of developing breast cancer 
around the menopausal age group.1 
WHO HISTOLOGICAL CLASSIFICATION OF TUMORS OF BREAST10 
EPITHELIAL TUMORS: 
Invasive ductal carcinoma, not otherwise specified  
              Mixed type carcinoma  
              Pleomorphic carcinoma  
              Carcinoma with osteoclastic giant cells  
              Carcinoma with choriocarcinomatous features  
              Carcinoma with melanotic features  
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Invasive lobular carcinoma  
Tubular carcinoma  
Invasive cribriform carcinoma  
Medullary carcinoma  
Mucinous carcinoma and other tumours with abundant mucin 
              Mucinous carcinoma  
Cystadenocarcinoma and columnar cell mucinous carcinoma  
              Signet ring cell carcinoma  
Neuroendocrine tumours  
             Solid neuroendocrine carcinoma  
            Atypical carcinoid tumour  
            Small cell / oat cell carcinoma  
            Large cell neuroendocrine carcinoma  
Invasive papillary carcinoma  
Invasive micropapillary carcinoma  
Apocrine carcinoma  
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Metaplastic carcinomas  
         Pure epithelial metaplastic carcinomas  
                 Squamous cell carcinoma  
                 Adenocarcinoma with spindle cell metaplasia  
Adenosquamous carcinoma  
Mucoepidermoid carcinoma  
        Mixed epithelial/mesenchymal metaplastic carcinomas  
 Lipid-rich carcinoma  
Secretory carcinoma  
Oncocytic carcinoma  
Adenoid cystic carcinoma  
Acinic cell carcinoma  
Glycogen-rich clear cell carcinoma  
Sebaceous carcinoma  
Inflammatory carcinoma  
Lobular neoplasia  
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                 Lobular carcinoma in situ  
Intraductal proliferative lesions  
                 Usual ductal hyperplasia  
                 Flat epithelial atypia  
                 Atypical ductal hyperplasia  
                  Ductal carcinoma in situ  
Microinvasive carcinoma  
Intraductal papillary neoplasms 
                  Central papilloma  
                  Peripheral papilloma  
                  Atypical papilloma  
Intraductal papillary carcinoma  
Intracystic papillary carcinoma  
Benign epithelial proliferations  
Adenosis including variants  
Sclerosing adenosis 
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                   Apocrine adenosis 
                   Blunt duct adenosis 
Microglandularadenosis 
Adenomyoepithelialadenosis 
        Radial scar / complex sclerosing lesion  
Adenomas  
                   Tubular adenoma  
                   Lactating adenoma  
                   Apocrine adenoma  
                   Pleomorphic adenoma  
                   Ductal adenoma  
MYOEPITHELIAL LESIONS  
Myoepitheliosis 
Adenomyoepithelialadenosis 
Adenomyoepithelioma 
Malignant myoepithelioma 
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MESENCHYMAL TUMOURS 
 Haemangioma  
Angiomatosis 
Haemangiopericytoma 
Pseudoangiomatous stromal hyperplasia  
Myofibroblastoma 
Fibromatosis (aggressive)  
Inflammatory myofibroblastic tumour  
Lipoma  
Angiolipoma 
Granular cell tumour  
Neurofibroma 
Schwannoma 
Angiosarcoma 
Liposarcoma 
Rhabdomyosarcoma 
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 Osteosarcoma  
 Leiomyoma  
Leiomyosarcoma 
 FIBROEPITHELIAL TUMOURS  
Fibroadenoma 
Phyllodes tumour  
                   Benign  
                   Borderline  
                   Malignant  
Periductal stromal sarcoma, low grade  
 Mammary hamartoma 
TUMOURS OF THE NIPPLE  
Nipple adenoma  
Syringomatous adenoma  
 Paget disease of the nipple  
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MALIGNANT LYMPHOMA  
Diffuse large B-cell lymphoma  
Burkitt lymphoma  
Extranodal marginal-zone B-cell lymphoma of MALT type  
Follicular lymphoma  
METASTATIC TUMOURS 
TUMOURS OF THE MALE BREAST  
Gynaecomastia 
 Carcinoma 
          Invasive  
          In situ  
Breast carcinomas can arise either from ducts or lobules and are called as 
ductal carcinoma or lobular carcinoma respectively. They are divided into further 
subsets in which, if the tumor is confined within the ducts or lobules it is known as 
ductal/lobular carcinoma in situ, if the tumor invades the surrounding stroma it is 
considered as invasive ductal/lobular carcinoma. 
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DUCTAL CARCINOMA IN SITU: 
The carcinomatous component predominantly arises and is confined within 
the terminal duct lobular unit. Few of the lesions can arise from larger ducts. They 
exhibit many morphological patterns such as papillary, solid, cribriform, 
micropapillary, clinging, cystic hypersecretory and comedo. Further these variants 
can be either low grade or high grade in nature. Comedo variant is considered as a 
high grade lesion whereas solid, cribriform, micropapillary variants are low grade 
lesions. Clinging variant can be of either high grade or lowgrade. A three tier 
grading systems is being followed, where high grade lesions are classified as grade 
3, low grade lesions are classified as grade 1, intermediate lesion are classified as 
grade 2.9 
TYPES OF DCIS: 
(i) COMEDOCARCINOMA: 
It is a high grade, centrally located tumor and can be multicentric at times. 
Macroscopically they are collection of thickened ducts within the breast tissue that 
become visible.  
Histopathology: 
The ducts are composed of tumor cells arranged in solid sheets. The cells 
exhibit marked pleomorphism with increased mitotic figures. This pattern of 
carcinoma can also involve the myoepithelial cells. Stroma surrounding the duct 
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shows a concentric type of fibrosis. Areas of calcification and necrosis are also 
noted. 
Two important aspects to consider in case of DCIS are the extent of 
involvement of the ducts and for features of invasion. In an invasive breast 
carcinoma when the DCIS component is more than 25% it is called as Extensive 
intraductal carcinoma.19 The main differentiating feature between extensive 
intraductal and classical invasive carcinomas is that the latter shows irregular 
invasiveness into the surrounding stroma.  
(ii) PAPILLARY CARCINOMA (IN SITU) 
It is a rare, low grade lesion commonly seen in the older age group. 
Macroscopically they appear to be well circumscribed lesion and are larger than 
papillomas. Histopathologically these neoplasms are composed of cells arranged 
in a papillary pattern. Cells are uniform in size, with high Nucleo-Cytoplamic 
ratio, hyperchromatic nuclei and inconspicuous nucleoli. Numerous mitotic figures 
are also noted. These tumors lack myoepithelial cells and have a scant stroma. 
(iii) SOLID FORM OF DCIS: 
The ducts are filled by sheets of tumor cells that are larger than cells of 
lobular neoplasia but small and uniform than that observed in comedocarcinoma 
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(iv) CRIBRIFORM PATTERN OF DCIS: 
The ducts are composed of sheets of tumor cells showing regular spaces 
interspersed within. When the size, shape and distribution of these spaces are more 
regular than the lesion is considered to be more malignant. These spaces can be in 
the form of either trabecular bars or roman bridges. In trabecular bars, there is a 
perpendicular orientation of nuclei in association with the long axis of the bar. 
Whereas in roman bridges the trabecular bars appear bent connecting two portions 
of the epithelial lining.9 
(v) MICROPAPILLARY VARITEY OF DCIS: 
This variant shows tumor cells arranged in a papillary pattern and it lacks 
central fibrovascular core. They appear as elongated epithelial projections into the 
lumen.  
(vi) CLINGING CARCINOMA: 
This variant shows tumor cells arranged in a glandular pattern. Usually they 
are lined by one to two layers of malignant epithelial cells. These tumor cells are 
carefully examined because they can exhibit marked pleomorphism and features 
similar to that of comedocarcinoma. Few of the lesions resemble low grade form 
of DCIS similar to that of micro papillary variant. 
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LOBULAR CARCINOMA IN SITU/LOBULAR NEOPLASIA: 
Lobular neoplasia accounts for about 1 to 4% of all breast cancer cases, it 
usually affects women of post-menopausal age group.10 Most of the lobular 
carcinomas are multicentric and can be bilateral. Mammogram appears normal 
except for few cases that show areas of calcification within the central necrosis. 
Usually it is an incidental finding in breast specimen that has been operated for 
some other lesion. Macroscopically there are no appreciable features. 
Histopathology: 
Lobular carcinoma in situ arises within terminal duct lobular unit with 
pagetoid involvement of the terminal ducts. The neoplasm is composed of 
monomorphic small round cells with uniform nuclei, fine chromatin and 
inconspicuous nucleoli. These cells expand the acini within the lobule but however 
the lobular architecture is preserved. Myoepithelial cells can also be identified in 
few cases where they are interspersed within the tumor cells. 
Lobular carcinoma in situ can be of two types namely10 
(i)Type A and  
(ii)Type B.  
Type A has a classical appearance as mentioned above were as type B 
shows pleomorphic nuclei with condensed chromatin and occasional conspicuous 
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nucleoli. Type B is also known as pleomorphic lobular neoplasia. If there is 
Pagetoid involvement, then they show a characteristic clover leaf or necklace 
appearance (who). When the terminal ducts near the lesion show features similar 
to that of those seen in the acini then it is called as pagetoid appearance. 
Lobular carcinoma in situ can be confused with lobular hyperplasia in 
which the latter shows smaller sized lobules with a central lumen. The risk of 
lobular carcinoma in situ developing into invasive cancer is around 20-30%.9 The 
risk of developing invasive carcinoma in the normal contralateral breast is also 
high. Hence lifelong periodical follow up is necessary. 
MICROINVASIVE CARCINOMA: 
It accounts for less than one percent of all breast carcinoma cases. They are 
usually less than or equal to one mm in size. Microscopically they show only tiny 
foci of invasion into the stroma. Rest of the tumor is noninvasive in nature. 
INVASIVE DUCTAL CARCINOMA, NOT OTHERWISE SPECIFIED: 
This type accounts for the largest group of invasive cancer. These 
carcinomas have no characteristic morphological appearance as that of tubular or 
lobular carcinoma. Breast carcinomas due to BRCA 1 mutation are mostly 
invasive ductal carcinoma, NOS in type.20 
Macroscopically these tumors have ill-defined margins with stellate 
outlines, firm in consistency and cut surface appears gritty with yellow specs. 
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Histopathologically tumor cells are arranged in tubules, cords, clusters and sheets. 
Cells are large with eosinophilic cytoplasm, pleomorphic nuclei, fine to coarse 
chromatin and prominent often multiple nucleoli. Variable mitosis are also seen. 
Most of the invasive carcinoma are associated with comedo type of ductal 
carcinoma in situ. Surrounding stroma show marked fibrosis with areas of 
sclerosis. Focal necrosis is also noted. Few of the variants of invasive ductal 
carcinoma not otherwise specified are: 
(i)MIXED TYPE CARCINOMA: 
For a tumor to be named as invasive ductal carcinoma not otherwise 
specified, it should have at least more than 50% of non-specialized patterns (who 
21). If the non-specialized pattern accounts only for about 10-49% and the rest of 
them show a recognized special type like tubular or lobular appearance, then it is 
called as mixed type carcinoma.10 
(ii)PLEOMORPHIC CARCINOMA: 
It is a type of invasive ductal carcinoma NOS, has a very rare occurrence. 
Most commonly, it occurs in people around the age group of 50 years. They 
present themselves as a palpable mass and few of the cases manifest themselves 
first as metastasis. Histopathologically the tumor comprises of highly pleomorphic 
tumor giant cells, which account for about 75% of the tumor and background show 
features of adenocarcinoma. Numerous mitotic figures are noted, 20/10Hpf. 
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Lymphovascular invasion can also be observed. Axillary node involvement is 
identified in more than half of the cases.10 
(iii)CARCINOMA WITH OSTEOCLASTIC GIANT CELLS: 
The tumor shows a well to moderately differentiated infiltrating ductal 
carcinoma, with surrounding stroma exhibiting fibroblastic reaction and increased 
inflammatory infiltrate of lymphocytes, monocytes and a few macrophages. 
Characteristic osteoclastic type giant cells are in the stroma that appears to 
surround the carcinomatous component along with hypervascular reactive stroma 
is also noted. 
(iv)CARCINOMA WITH CHORIOCARCINOMATOUS FEATURES: 
Most of the patients with ductal carcinoma NOS have elevated beta 
chorionic gonadotropin levels in blood. The individual tumor cells are also 
positive for beta HCG. Choriocarcinomatous differentiation is very rare and it is 
seen between 5th to 6th decades of life. 
(v)CARCINOMA WITH MELANOTIC FEATURES: 
These tumors are biphasic and composed of invasive ductal carcinoma 
component and malignant melanomatous component. It should be differentiated 
from breast cancers that invade the skin and involve dermo-epidermal junction 
which leads to deposition of melanin pigment. Most of melanocytic lesions seen 
within the breast tumor are due to metastasis from malignant melanoma elsewhere. 
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Primary malignant melanoma involving the nipple areolar complex is extremely 
rare.  
           Prognosis of these tumors depends upon the size, grade, vascular invasion 
and hormonal receptor positivity. Overall ten year survival rate is between 35 and 
50%.21 
INVASIVE LOBULAR CARCINOMA: 
Account for about 5-15% of invasive breast carcinoma. Mean age group 
affected is 50yrs; increase in incidence is mostly attributed to the increase in 
hormone intake in the form of hormone replacement therapy. They are usually 
centrally located sometimes can be multicentric and bilateral. Mammogram shows 
architectural distortion.10 
Macroscopically they appear as an ill-defined lesion with a diffuse growth 
pattern. Microscopically the tumor cells are poorly cohesive and appear to be 
dispersed singly in a fibrous stroma. Few areas show tumor cells that are arranged 
in cords and infiltrating the stroma. Cells have ovoid nuclei, thin rim of cytoplasm 
with occasional intracytoplasmic luminal formation.  
Other variants of invasive lobular carcinoma includes   
(i) Solid pattern – sheets of uniform cells that are tightly packed and shows a 
lobular arrangement.  
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(ii) Alveolar pattern – it is similar to that of lobular carcinoma, where the tumor 
cells are arranged in globular aggregates. 
(iii) Pleomorphic lobular pattern- similar to that of typical lobular carcinoma but 
the tumor cells exhibit marked pleomorphism.  
Nodal metastasis is lower than that of IDC, these tumors more commonly 
metastasize to bone, GIT, uterus, meninges and ovary whereas IDC commonly 
involves the lungs. Alveolar variant of invasive lobular carcinoma is considered 
low grade whereas pleomorphic invasive lobular carcinoma has a very poor 
prognosis. 
TUBULAR CARCINOMA: 
It is a rare variant of breast carcinoma occurring in the elderly age group which 
accounts for about 2% of invasive breast cancers10. Mammogram shows a 
characteristic spiculated appearance. Macroscopically the tumor is smaller in size 
with an average of 1cm. Morphologically there is two types (i) pure type and 
(ii)the sclerotic type.22 Pure type has a stellate appearance whereas sclerotic type is 
more diffuse in nature. 
Histopathology: 
These tumors are composed of tubules that have a characteristic angulated 
appearance with open lumens that are lined by a single layer of epithelial cells 
which are small, regular and exhibits mild nuclear pleomorphism. There should be 
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minimum 90% of tubules identified in the lesion and should not have 
multilayering or marked nuclear pleomorphism, if present it excludes the 
diagnosis of tubular carcinoma. Surrounding stroma shows marked Desmoplastic 
reaction. Tubular carcinoma can also accompany other epithelial proliferative 
lesions like ductal carcinoma in situ or lobular neoplasia. This variant has an 
excellent prognosis as compared to that of invasive ductal carcinoma, NOS. 
INVASIVE CRIBRIFORM CARCINOMA: 
Common age group affected is around 5th decade of life and accounts for 
1-3.5% of breast carcinomas.10 Mammogram shows speculated appearance with 
microcalcifications.  
Histopathology: 
Tumor is predominantly composed of cells arranged in a cribriform pattern 
and islands which show stromal invasion. Cells exhibit moderate pleomorphism. 
Tumor islands are surrounded by reactive fibrous stroma. These variants are also 
found in association with intraductal carcinoma and tubular carcinoma. Invasive 
cribriform carcinoma has a good prognosis and ten year survival rate is 90%.10 
MEDULLARY CARCINOMA  
Medullary carcinoma accounts for about 1 to 7% of all breast cancers and 
the common age group affected is between 4th to 5th decade of life.10 Medullary 
carcinomas are seen more common in patients with BRCA 1 mutation.23 
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Mammogram shows a well-defined lesion and mimics a benign tumor. Grossly the 
tumor is well circumscribed, cut surface of which is grey white and homogenous. 
It has a similar appearance to that of fibroadenoma except that of whorling and slit 
like spaces. Areas of hemorrhage and necrosis are also noted. 
Histopathology: 
These tumors have five important characteristic microscopic features:  
The tumor should be well circumscribed;  tumor cells are predominantly arranged 
in sheets; there should not be any glandular or tubular structures; surrounding 
stroma should have dense lympho-plasmacytic infiltrate; tumor cells are round 
with abundant cytoplasm, Pleomorphic vesicular nuclei and prominent nucleoli, 
mitosis and atypical giant cells are also seen;. Necrosis and squamous 
differentiation can also be seen. 
Hormonal receptor status shows triple negativity for ER, PR and Her2 neu. 
Has a better prognosis that infiltrating ductal carcinoma NOS. Only 10% of the 
cases show lymph node metastasis if the metastatic deposits are found in more 
than three axillary lymphnodes, it is considered to have a poor prognosis.10 
MUCIN PRODUCING CARCINOMAS: 
It includes all breast carcinomas that have features of producing mucin. 
There are four important types of mucin producing carcinomas 
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(i)Mucinous carcinoma: 
Accounts for 2% of all breast cancer.10 Mammogram shows a well-defined, 
lobulated lesion, looks more or less similar to a benign tumor. Grossly the tumor is 
soft and cut surface appears gelatinous and glistening. Histopathologically the 
tumor cells are uniform and are seen floating in lakes of mucin. These mucinous 
lakes are separated by fibrous tissue into compartments. Few of the tumors have 
intraepithelial component and rarely exhibits neuroendocrine differentiation. Pure 
mucinous carcinoma of breast has a very good prognosis, only handful of cases 
show axillary node metastasis. 
(ii)Mucinous cystadenocarcinoma and columnar cell mucinous carcinoma: 
These tumors have clinical and radiological features similar to that of 
infiltrating ductal carcinomas. Macroscopically they are cystic and have a 
gelatinous appearance. Microscopically both the types comprise of tall columnar 
mucinous cell with abundant intracytoplasmicmucin and basal nuclei. If they have 
a cystic appearance then they are called mucinous cystadenocarcinoma or if they 
have a solid appearance then they are called as columnar cell mucinous carcinoma. 
These tumor cells can also be arranged in papillary fronds.  
(iii)Signet ring cell carcinoma: 
There are two variants; one of the types has cytoplasmic lumina which 
pushes the nuclei to one side of the cell. Other type resembles that of gastric 
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carcinoma where the cytoplasm is filled with acid mucinous substance and pushes 
the nuclei towards one pole. 
NEUROENDOCRINE TUMORS: 
It accounts for about 2-5% of breast cancers. It occurs between 6th to 7th 
decades of life.24 Mammogram shows a well circumscribed lesion. 
Macroscopically they appear as an expansile tumor which can be gelatinous at 
times. Microscopy shows tumor cells arranged in characteristic nesting pattern and 
in solid sheets with peripheral palisading of cells. There are different subtypes 
which includes 
(i)Solid neuroendocrine carcinoma 
Tumor cells are arranged in nests and trabeculae separated by 
fibrovascularstroma. They exhibit a lobular pattern. Cells are small with round to 
oval nuclei and stippled chromatin. Mitotic figures are also noted 
(ii)Small cell / oat cell carcinoma: 
Tumor shows an invasive growth pattern and composed of cells that are 
small with hyperchromatic nuclei. They appear similar to that of small cell 
carcinoma occurring in the lungs both morphologically and 
immunohistochemically. 
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(iii)Large cell neuroendocrine carcinoma: 
Cells are arranged in clusters, they are large with abundant cytoplasm, 
vesicular nuclei and numerous mitotic figures are also noted 
These neuroendocrine tumors can be graded as well, moderately and poorly 
differentiated. Well differentiated carcinomas have a better prognosis than high 
grade tumor.  
INVASIVE PAPILLARY CARCINOMA: 
It accounts for about 1-2% of invasive breast carcinomas.10 These tumors 
are diagnosed in women in the post-menopausal age group. Mammogram shows 
nodular densities that are multiple and at times can be lobulated. Macroscopically 
tumor appears fairly circumscribed and has features similar to that of invasive 
ductal carcinoma nos.  
Histopathology: 
Tumor is well circumscribed and the tumor cells are arranged in a papillary 
pattern. Cells have amphophilic cytoplasm, exhibiting moderate amount of 
pleomorphism and few may show apocrine changes. Surrounding stroma is scant 
and these tumors can also show abundant extracellular mucin. More than 75% of 
cases are associated with DCIS component. It has a better prognosis compared to 
that of invasive ductal carcinoma, NOS.10 
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INVASIVE MICROPAPILLARY CARCINOMA: 
This variant accounts for less than 2% of all breast cancer cases. They 
usually present themselves at first clinically with axillary lymph node metastasis.25 
Macroscopically they have a lobulated outline indicating they have an invasive 
growth. Microscopy shows clusters of tumor cells exhibiting moderate nuclear 
pleomorphism and they are surrounded by a clear stromal space which has been 
created artifactually.  
APOCRINE CARCINOMA: 
It constitutes about 4% of all invasive carcinomas. Mammogram shows 
feature similar to that of invasive ductal carcinoma, NOS. Microscopically any 
type of invasive breast carcinoma can show apocrine changes. The term apocrine 
carcinoma is only applicable when there are more than 90% of tumor cells 
showing apocrine changes. These changes are also noted in ductal / lobular 
carcinomas in situ. There are two types of cells namely type A and type B.10 Type 
A cell are large with abundant eosinophilic cytoplasm, has globoid nuclei with 
prominent nucleoli. They appear like granular cell tumors. Type B cells have 
abundant cytoplasm with many vacuolations within. These cells are similar to that 
of macrophage.  
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METAPLASTIC CARCINOMA: 
It accounts for less than 1% of breast carcinoma. They are heterogenous 
tumors which can be 
Epithelial: 
(i) Squamous  
(ii) Adenocarcinoma with spindle cell differentiation 
(iii) Adenosquamous, including mucoepidermoid (or)  
Mixed epithelial-mesenchymal: 
(i)Carcinoma with chondroid metaplasia 
(ii)Carcinoma with osseous metaplasia 
(iii)Carcinosarcoma 
*Epithelial tumors - Squamous cell carcinoma: The carcinoma is composed of 
metaplastic squamous cells. Can be of keratinizing type/non keratinizing type or 
spindle in type. They are not derived from skin or metastasis from elsewhere.  
*Adenocarcinoma with spindle cell metaplasia: The tumor is well circumscribed 
composed of tubules of adenocarcinoma interspersed with atypical spindle cells. 
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*Adenosquamous carcinoma: These tumors composed of characteristic 
adenocarcinomatous component interspersed with solid nests of squamous 
differentiation 
*Mixed epithelial/mesenchymal metaplastic carcinomas: 
They are considered as matrix producing carcinomas. Adenocarcinoma is 
mixed with areas showing mesenchymal components like chondroid or osseous 
differentiation. Sometimes it can be full blown sarcoma. Usually the mesenchymal 
component appears benign. If they are malignant then they are termed as 
carcinosarcoma. 
Generally metaplastic tumors of pure epithelial type and mixed 
epithelial/mesenchymal type has a five year survival rate of about 60%. Among 
which carcinosarcomas are considered as a highly aggressive variant. 
LIPID RICH CARCINOMA: 
It accounts for about 1-6% of breast carcinoma cases. Patients often present 
with Paget’s disease of nipple. Histopathologically these tumors show grade III 
morphology, the cells are large with foamy cytoplasm. There should be a 
minimum of 90% of neoplastic cells containing neutral lipids that should be 
demonstrable. 
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SECRETORY CARCINOMA: 
It is a rare tumor with frequency of 0.15% of all breast carcinomas. It 
affects children as well as adults and is situated near the areola. Macroscopically 
they appear as a well circumscribed greyish white to tan nodule. 
Histopathologically they are found in three patterns 
(i) Microcystic pattern,  (ii) solid pattern and  (iii) a tubular pattern.  
Cells are large with abundant pale granular cytoplasm, round to oval nuclei 
with occasional small nucleoli. Intracytoplasmic lumina are seen. Sometimes these 
lumina coalesce together and form microcystic structure. Secretions are also found 
within the lumina which is strongly PAS positive. Has a very good prognosis for 
children but has an aggressive behavior in adults. 
ONCOCYTIC CARCINOMA: 
Incidence is very rare. They can be misdiagnosed as apocrine carcinoma. 
Seen in patients around 60yrs of age. Histopathologically the tumor is 
circumscribed and composed of cells arranged in a glandular pattern and solid 
sheets. The cells have abundant eosinophilic granular cytoplasm, round to oval 
monomorphic nuclei with inconspicuous nucleoli. More than 70% of cells should 
have oncocytic appearance.10 
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ADENOID CYSTIC CARCINOMA: 
Its a rare type of breast carcinomas. It has low aggressive behaviour and is a 
counterpart of histologically similar tumor arising in salivary glands. Usually these 
tumors are bilateral and are situated around sub-periareolar region. 
Macroscopically they are well circumscribed lesion, cut surface of which appears 
pink or tan. Histopathologically three patterns can be made out (i) trabecular-
tubular (ii) cribriform (iii) solid. Classically the cells are arranged in fenestrated 
nests or in tubules, cells can be either basaloid in nature with scant cytoplasm or 
cells with eosinophilic abundant cytoplasm with basaloid type of nucleus. It is a 
low grade malignant tumor and has a good prognosis, doesn’t spread via 
lymphatics. 
ACINIC CELL CARCINOMA: 
A very rare tumor is observed in females around 5th decade of life. These 
tumors are considered as the counterpart of similar tumor that is found in the 
parotid gland. Microscopy shows cells are arranged in microcystic and 
microglandular pattern, with abundant eosinophilic granular cytoplasm, 
pleomorphic nuclei and occasional prominent nucleoli. Mitotic figures can be upto 
15mitoses/10Hpf.10 
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GLYCOGEN RICH, CLEAR CELL CARCINOMA: 
It accounts for about 1-3% of all invasive breast carcinomas. Median age is 
57 yrs. Macroscopically it appears similar to that of invasive or DCIS. 
Histopathologically the cells are arranged in solid nests and few of them show the 
tubular or papillary pattern, the cells are polygonal in shape, shows clear 
cytoplasm with hyperchromatic nuclei and prominent nucleoli. They are also 
associated with ductal carcinoma in situ component. More than 90% of cells 
should have clear cytoplasm containing glycogen. These tumors have more 
aggressive behaviour than usual ductal carcinoma. Most of the cases show axillary 
lymph node metastasis. 
SEBACEOUS CARCINOMA: 
It’s a very rare variant. Gross appearance shows a well delineated tumor, 
cut surface of which appears yellow. Histopathologically tumor cells are arranged 
in lobules composed of sebaceous cells mixed with small ovoid to spindle cells. 
The cytoplasm of sebaceous cells is abundant with vacuolations whereas the 
cytoplasm of the spindle/ ovoid cells is scant. Nuclei of both the cells appear 
vesicular with occasional prominent nucleoli. Few mitotic figures are noted.  
INFLAMMATORY CARCINOMA: 
These tumors show a characteristic feature of the dermal lymphatic 
invasion from an underlying invasive ductal carcinoma. Most commonly found in 
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women of a younger age group. Grossly there is edema, peau d’orange and 
induarated appearance of skin overlying the breast. Puckering of nipple can also 
be noted. Microscopy shows tumor cells with grade 3 morphology with evidence 
of dermal lymphatic invasion. Despite the name these tumors show only minimal 
lympho-plasmacytic infiltrate. These tumors are straight away graded as T4d and 
have a very poor prognosis with 5 year survival rates is less than 5%.10 
NOTTINGHAM MODIFICATION OF SCARFF – BLOOM – 
RICHARDSON GRADING:26 
This grading system was proposed by Ellis and Elston. It is a semi quantitative test 
TUBULE FORMATION: 
1   Point >75% 
2   Points 10-75% 
3   Points < 10% 
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NUCLEAR PLEOMORPHISM: 
1    Point Minimal pleomorphism 
2   Points Moderate pleomorphism 
3   Points marked pleomorphism 
 
MITOTIC COUNT: 
Points are provided depending upon the number of mitosis counted in a particular 
determined field area 
Field diameter (mm) 0.44 0.59 0.63 
Filed area (mm2) 0.152 0.274 0.312 
Mitotic count    
1 point 0-5 0-9 0-11 
2 points 6-10 10-19 12-22 
3 points >11 >20 >23 
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GRADES: 
Grade 1: well differentiated breast carcinoma : 3-5 points 
Grade 2: moderately differentiated breast carcinoma : 6-7 points 
Grade 3: poorly differentiated breast carcinoma : 8-9 points 
 
TNM CLASSIFICATION OF CARCINOMAS OF THE BREAST:27 
T: Primary Tumor  
TX: Primary tumor cannot be assessed  
T0: No evidence of primary tumor  
Tis: Carcinoma in situ  
Tis (DCIS): Ductal carcinoma in situ  
Tis (LCIS): Lobular carcinoma in situ  
Tis (Paget): Paget disease of the nipple with no invasive or in-situ carcinomatous 
component 
If Paget disease is found in association with invasive or carcinoma in situ 
component, then they are classified according to the size of the tumor.  
T 1: Tumor = 2 cm in greatest dimension 
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T 1 mi: Microinvasion = 0.1 cm in greatest dimension 
T 1a Tumor > 0.1 cm but = 0. 5 cm in greatest dimension 
T 1b Tumor > 0.5 cm but = 1 cm in greatest dimension  
T 1c Tumor > 1 cm but = 2 cm in greatest dimension 
T 2 Tumor > 2 cm but = 5 cm in greatest dimension 
T 3 Tumor > 5 cm in greatest dimension  
T4 Tumor of any size with direct extension to chest wall or skin  
T4a to T4d Note:Chest wall includes ribs, intercostal muscles, and serratus 
anterior muscle but not pectoral muscle.  
T4a Extension to chest wall  
T4b Edema (including peau d’orange), or ulceration of the skin of the breast, or 
satellite skin nodules confined to the same breast  
T4c Both 4a and 4b, above  
T4d Inflammatory carcinoma  
STAGING OF NODAL METASTASIS: 
N – Regional Lymph Nodes  
NX: Regional lymph nodes cannot be assessed (e.g. previously removed)  
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N0: No regional lymph node metastasis 
N1: Metastasis in movable ipsilateral axillary lymph node(s)  
N2a: Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to 
other structures  
N2b: Metastasis only in to ipsilateral internal mammary lymph node(s) and in the 
absence of clinically evident axillary lymph node metastasis  
N3a: Metastasis to ipsilateral infraclavicular lymph node(s)  
N3b: Metastasis to ipsilateral internal mammary and axillary lymph nodes  
N3c: Metastasis to ipsilateral supraclavicular lymph node(s) 
STAGING OF METASTASIS: 
M: Distant Metastasis 
MX: Distant metastasis cannot be assessed  
M0: No distant metastasis 
M1: Distant metastasis 
pTNM Pathological Classification 
pT: Primary Tumor  
pN: Regional Lymph Nodes  
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pNX: Regional lymph nodes cannot be assessed which are previously removed  
pN0: No regional lymph node metastasis 
pN0(i-): with negative immunohistochemsitry 
pN0(i+): tumor cells in regional lymphnodes less than 0.2 cm (detected by H and 
E or IHC) 
pN0(mol-): negative molecular findings using RT-PCR 
pN0(mol+): positive molecular findings on using RT-PCR, but without 
histological or immunohistochemical findings. 
pN1a: Metastasis in 1-3 axillary lymph node(s), including at least one larger than 2 
mm in greatest dimension  
pN1b: Internal mammary lymph nodes with microscopic metastasis detected by 
sentinel lymph node dissection but not clinically apparent  
pN1c: Metastasis in 1 - 3 axillary lymph nodes and internal mammary lymph 
nodes with microscopic metastasis detected by sentinel lymph node dissection but 
not clinically apparent 
pN2a: Metastasis in 4-9 axillary lymph nodes, including at least one that is larger 
than 2 mm 
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 pN2b: Metastasis in clinically apparent internal mammary lymph node(s), in the 
absence of axillary lymph node metastasis 
pN3a: Metastasis in 10 or more axillary lymph nodes (at least one larger than 2 
mm) or metastasis in infraclavicular lymph nodes  
pN3b Metastasis in clinically apparent internal mammary lymph node(s) in the 
presence of one or more positive axillary lymph node(s); or metastasis in more 
than 3 axillary lymph nodes and in internal mammary lymph nodes with sentinel 
node biopsy but not clinically seen. 
pN3c Metastasis in the ipsilateral supraclavicular lymph node(s) 
 
DISTANT METASTASIS: 
M0: no evidence of distant metastasis ( clinically and radiologically) 
Cm0(i+): no radiological/clinical evidence of metastasi, but molecular or 
microscopic detection of tumor deposits in circulating blood, bone marrow, non-
regional nodal tissue that are =0.2 cm 
M1: distant detectable metastasis determined clinically or radiographically and/or 
histological evidence of deposits >0.2cm 
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TNM STAGING OF BREAST CARCINOMA29 
Stage 0 Tis N0 M0 
Stage 1 T1 N0 M0 
Stage II A T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage II B T2 N1 M0 
 T3 N0 M0 
Stage III A T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1,N2 M0 
Stage III B T4 N0,N1,N2 M0 
Stage III C Any T N3 M0 
Stage IV Any T Any N M1 
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PROGNOSTIC AND PREDICTIVE FACTORS: 
Prognosis of breast carcinoma depends mainly upon clinical and 
pathological factors. Most of the women diagnosed are expected to have a normal 
life expectancy but rest of the patients have a poor prognosis, which includes those 
who presented with distant metastasis or inflammatory carcinoma.  
Prognosis of breast cancer depends upon two entities:1 
(i) Extent of the cancer and  
(ii) Biology of the cancer.  
It is essential to find out the prognosis of the patient which can be helpful for 
counselling them and also devising a treatment strategy accordingly. We can also 
motivate and plan for clinical trials. 
PROGNOSTIC FACTORS DEPENDING UPON THE EXTENT OF 
TUMOR ARE: 
1. Invasive carcinoma vs ductal carcinoma in-situ: 
The presence or absence of invasiveness is considered as one of the major 
prognostic factor. Ductal carcinoma in situ in general has an excellent prognosis. 
Rarely they are invasive and mastectomy can provide surgical cure. But if DCIS 
component is found to be multicentric, then there is a high possibility of finding an 
invasive occult carcinoma elsewhere in the breast.27 Comedocarcinoma variant of 
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DCIS, is a high grade lesion that can metastasize to lymph node without showing 
any features of invasion. 
2. Lymph node metastasis: 
Axillary lymph node metastasis is one of the most important prognostic 
factor among all the other factors. It should always be evaluated by 
histopathological examination of a biopsied specimen because clinical 
examination for nodal involvement can give either a false positive results, were 
reactive nodes become palpable or false negative results, were micrometastasis 
cannot be palpated. If the axillary nodes are free of tumor then the 10 year survival 
rate is about 70% - 80%, when one to three nodes are positive the survival rate is 
reduced by 35% to 40%. If ten and more nodes are involved the survival rate is 
only 10% to 15%.1 In breast carcinoma all the lymphatic channels initially drains 
into the first lymph node and it is known as sentinel lymph node. This particular 
node can be identified using dyes and biopsy is taken from them to rule out 
metastasis, if sentinel lymph node shows no evidence of metastasis then rest of the 
nodes are highly unlikely to show any evidence of metastasis. Few of the patients’ 
presents with recurrence of tumour and distant metastasis even in the absence of 
axillary lymph node involvement, due to presence of metastasis in internal 
mammary lymph nodes or rarely by a haematogenic spread. 
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3. Distant metastasis: 
If the patients are diagnosed to have distant metastasis, then there is no cure 
available. Distant metastasis if present is considered as an important prognostic 
factor than that of axillary lymph node metastasis. 
4. Size of the tumor: 
When the tumor size increases the prognosis becomes poor. The chance of 
nodal metastasis is directly proportional to the tumor size. If the size of a tumor is 
1cm and there is no nodal metastasis, the 10 year survival is around 90%. If size is 
2cm then survival rate comes down to 77%. When both ER and Her 2 receptor 
status are negative, the prognosis is regarded as poor even if the tumor is less than 
1cm without any nodal involvement. Microscopic evaluation of tumor size has a 
greater significance than that of measuring the size macroscopically. The term 
minimal breast carcinoma is used when all the carcinoma in-situ components and 
invasive component are less than or equal to 1cm.1 
5. Local extension of the lesion: 
When breast carcinoma involves the overlying skin or underlying skeletal 
muscle, the surgical treatment becomes difficult. But recently due to early 
detection of breast cancer and better awareness, this has become a rare 
presentation. 
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6. Inflammatory carcinoma: 
Breast cancers can also present with thickened and erythematous skin that 
becomes oedematous and adheres with Coopers ligament. Grossly it appears as 
surface of orange peel hence they are also called as peau d’orange in appearance. 
These tumors are not palpable and present only with the symptom of swollen 
breast which can be mistaken for a breast abscess. Microscopically the 
characteristic infiltration of dermal lymphatic channels by tumor cells are seen 
which completely blocks the lymphatic drainage. As they don’t have any 
characteristic histological or molecular evidence they are termed as inflammatory 
carcinoma, has a very grave prognosis and 3 year survival rates is only around 3% 
to 10%.1 
7. Lymphovascular invasion: 
More than half of invasive breast carcinoma cases show features of tumor 
cells infiltrating into the lymphatic spaces and blood vessels. It indicates that there 
is a high chance of recurrence even though there may not be any nodal metastasis 
and usually correlates with the presence of axillary lymph node metastasis. It is a 
poor prognostic factor.28 
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PROGNOSTIC FACTORS RELATED TO TUMOR BIOLOGY: 
1. Molecular subtype: 
ER, PR and Her 2 receptor expression by breast tumors play an important 
role in determining the prognosis of the patient. ER positive tumors have a better 
prognosis in terms of longer disease free survival rate than others. 
2. Cytoarchitectural types: 
Morphological variants of invasive breast carcinoma in general have a 
better prognosis than invasive breast carcinoma not otherwise specified. Tubular, 
lobular, papillary and adenoid cystic carcinoma variants generally have a good 
prognosis. Whereas metaplastic carcinoma, micropapillary carcinoma and signet 
ring cell variant of lobular carcinoma has a very poor prognosis. 
3. Histological grade: 
Invasive breast carcinomas are graded using a Nottingham modification of 
the Bloom-Richardson system. The system includes parameters like tubule 
formation, nuclear atypia and number of mitosis detected. So depending upon 
semi-qualitative assessment of the parameters, a final grading of well, moderate 
and poor differentiation is made out.26  
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4. Proliferative index: 
Proliferation of tumor cells can be assessed by mitotic count measurement 
in a particular field area or by using immunohistochemical markers like MIB-1 or 
Ki-67. Proliferative index is important for ER positive and HER 2 negative cases 
whereas ER negative and HER 2 positive receptor cases always has a high 
proliferative index.1 When there is increased proliferation it denotes a poor 
prognosis. But these patients can respond better to chemotherapy than other 
modalities of treatment. 
5. ER, PR and HER2 receptors: 
Breast carcinoma cases that express both ER and PR receptors respond well 
to hormonal treatment and hence have a good prognosis. Around 80% of patients 
with both the receptors positive respond well to treatment. But if there is 
expression of only ER or PR receptor alone the response to hormonal treatment is 
reduced to about 40%. If the patient is ER negative then the patient may respond 
well to chemotherapy than hormonal therapy, HER2 expression denotes the 
patients have a poor survival rate. 
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Other factors that play a substantial role in prognosis are: 
Age at presentation: 
Breast carcinoma detected below the age group of 50 years has a better prognosis 
than those who were detected above 50 years. Whereas younger women detected 
with breast cancer who were below the age group of 35 years has prognosis 
similar to that seen in older women. These patients will have a high grade lesion 
and chances of relapse are significantly higher.29 
BRCA 1: 
Breast carcinoma with BRCA 1 mutation has an overall shorter disease free 
interval. BRCA 1 expression on tumor cells can be detected using 
immunohistochemical stains. Depending upon the expression prognosis varies. If 
there is a reduced cytoplasmic expression the tumor has more chances of 
relapsing, when nuclear expression is reduced the tumor tends to have a poor 
prognosis. 
Pregnancy: 
When breast carcinoma manifests at the time of pregnancy or during 
lactation, it is found that the tumor shows low expression of ER/PR receptors and 
high expression of HER 2 receptors which in turn indicates the prognosis is poor 
and 5 year survival rate is only around 15% to 35%.30 
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Margins of tumor: 
Tumors with infiltrative margins have a poor prognosis than those with 
pushing type of margins. It is usually noted in medullary type of carcinomas. 
Tumor necrosis: 
Necrosis is usually noted in high grade lesions and indicates there are more 
chances of nodal metastasis which points towards a poor prognosis. 
Stromal reaction: 
Breast carcinomas with no inflammatory reaction have a better prognosis 
and reduced incidence of nodal metastasis. Tumors exhibiting a greater degree of 
elastosis respond well to hormonal management than those with no elastosis. Also 
if there is a central fibrotic scar in the portion of a tumor it indicates hypoxia and 
lymph angiogenesis which are considered as an indicator for a bad prognosis. 
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An American joint committee on cancer has proposed a classification that 
correlates the disease with ten year survival rates. 
American joint committee on cancer and Union Contre Le cancer staging:31 
STAGE 
PRIMARY 
CANCER 
LYMPHNODES 
( metastasis ) 
DISTANT 
METASTASIS 
10-YEAR 
SURVIVAL 
RATE 
0 DCIS or LCIS No Absent 92% 
I Invasive ca ≤ 2 cm No / micrometastasis Absent 87% 
II 
Invasive ca > 2cm 
Invasive ca > 5cm 
but ≤ 5cm 
1 to 3 +ve 
0 to 3 +ve 
Absent 
Absent 
65% 
III 
Invasive ca > 5cm 
Any size invasive ca 
Invasive ca with skin 
or chest wall 
involvement or 
inflammatory ca 
-ve or +ve 
≥ 4 +ve 
-ve or +ve 
 
 
Absent 
Absent 
Absent 
40% 
IV 
Any size invasive 
carcinoma 
-ve or +ve 
 
present 5% 
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IMMUNOHISTOCHEMISTRY: 
Immunohistochemistry is defined as the process of detecting antigens (e.g., 
proteins) in cells of a tissue section by exploiting the principle of antibodies 
binding specifically to antigens in biological tissues.  
So with the help of immunohistochemistry in breast carcinoma, prognosis 
and predictive value for the patients can be determined. But recently it has been 
identified that the expression of receptors using IHC markers is helpful in 
prediction of response to hormonal therapy than that of prognosis. 
ESTROGEN RECEPTOR: 
Estrogen receptor positive breast carcinomas are considered to have a good 
prognosis because they respond well to hormonal treatment. Recent studies 
indicate more than 70% of breast cancer cases in general shows ER receptor 
positivity, one of the study conducted portrays that nearly all patients with grade I 
tumor are found to be ER positive.32 Many studies stress the fact that PR receptor 
positive cases can also determine the outcome of patients, it is derived from the 
stats that depicts patients with ER and PR positive status together has a better 
prognosis than that compared to ER positive and PR negative receptors. 
As with any IHC studies there are some factors which play an important 
role in the outcome of the result. These include fixation time, processing quality, 
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antigen retrieval method and a clone of the antibody used which have been 
described below. 
Specimen type and fixation time: 
IHC studies in breast carcinoma can be done either in a biopsy sample or in 
a resected section. Few studies showed that IHC results were false negative in 
about 9% in resected sections than in biopsied specimen. The sole reason 
attributed to a false negative result is due to inadequate fixation of the sample in 
formalin. So it was proposed that the least required time to fix resected tissue in 
formalin is 6 to 8 hours for better estimation of ER positivity.33 
Selection of type of antibody: 
Choice of antibody used in IHC study is of prime importance because it 
should be strong enough to attach to the corresponding antigens and the results 
obtained should correlate with the clinical outcome of the patient. 1D5, 6F11 and 
SP1 are the three strong antibodies that provide better results.34 Out of which SP1 
monoclonal antibody is considered superior. 
Interpretation of the IHC expression depends upon two factors 
(i) Distribution of staining among tumor cells 
(ii) Intensity of staining 
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Though using IHC for determining ER receptor status has been used for a long 
time since, still there were some errors among pathologists in classifying weak ER 
positive cases and ER negative cases. Most of the weak ER positive cases are 
mislabeled as ER negative cases, thus devoiding them of treatment with hormones. 
So to prevent the discordance, a nine points scoring system was proposed by 
Allerd, Harvey et al and it was named as Allred scoring system. It is a 
semiquantitative test which takes into account the proportion of cells stained and 
the intensity of staining.35 
Proportion score Nuclear staining Intensity score 
Observation 
(intensity) 
0 No staining 0 No staining 
1 < 1% 1 Weak 
2 1-9% 2 Intermediate 
3 10-32% 3 strong 
4 33-65%   
5 66-100%   
 
The final Allred score is the sum of proportion and intensity scores, if the 
total score is 0-2 then the expression is negative, when the score is 3-8 receptor 
expression is considered positive. 
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Estimation of concentration of the receptors within the tumor is of clinical 
importance as they influence the optimal selection of treatment for the patients by 
clinicians and in turn reflects the prognosis and survival of the patient. So by using 
the Allred score, a cut off value for the treatment of breast carcinoma is 
formulated by Robin Leake and et al which is as follows:36 
score Response to treatment 
0 Endocrine treatment will not work 
2-3 20% chance of response to endocrine treatment 
4-6 50% chance of response to endocrine treatment 
7-8 75% chance of response to endocrine treatment 
 
 HUMAN EPIDERMAL RECEPTOR PROTEIN – 2: 
It is an oncogene protein and one of the transmembrane receptor 
glycoprotein belonging to the epidermal growth receptor family. In breast 
carcinomas expression of HER 2 receptors play a significant role in prognosis and 
outcome of the patient. HER 2 receptor positivity predicts the sensitivity of 
treatment to anthracycline based drug regimens and can be treated with 
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trastuzumab which is a form of targeted therapy, whereas they don’t respond well 
to hormonal treatment. There are also factors similar to that of ER receptor which 
affects the outcome of the result. Common methods for determining the HER 2 
receptor status are by IHC or FISH. But there is a difference in concordance 
values between the two. According to the new guidelines proposed by ASCO-
CAP, it is necessary that the sections should be fixed for a minimum of 6 hrs to a 
maximum of 48 hrs, core biopsy specimen should be fixed minimum for one hour. 
They have also created FDA scoring system to reduce the concordance between 
FISH and IHC results. 
FDA scoring system for HER 2:37 
Score Observation 
0 
 
No immunostaining 
 
1+ 
 
Weak immunostaining, < 30% of tumor cells 
 
2+ 
Complete membranous staining, either uniform or weak in at least 
10% of cells 
 
3+ Uniform intense membranous staining in at least 30% of cells 
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BRCA 1 : 
BRCA 1 located on chromosome 17 is found to be mutated in many 
familial breast and ovarian carcinomas. It is a type of germline mutation showing 
loss of hetrozygosity pattern suggesting to the fact that these are tumor suppressor 
gene. BRCA 1 has A growth regulatory function of breast epithelial cells. So when 
there is a BRCA 1 mutation it acts as a negative regulation of proliferation of 
epithelial cells. BRCA 1 and BRCA 2 accounts for about       80-90% of all the 
familial / hereditary cancers. BRCA 1 gene is of prime importance is that these 
susceptible genes when undergo mutational changes and being inherited by an 
individual not only causes risk of getting breast carcinoma but also prone to 
develop ovarian carcinoma around 10-20%.6 Whereas the propensity to cause 
breast cancer is far more less that of breast cancer caused by mutated BRCA 1 
gene. These two genes are also likely to cause epithelial cancers mostly involving 
the prostate and pancreas. BRCA1 plays an important role in check point 
activation and DNA repair, thereby preventing DNA damage. BRCA 2 has a 
significant role in homologous recombination. When BRCA 1 gene is mutated, 
risk of acquiring breast carcinoma is 56% to 90% whereas when BRCA 2 is 
mutated the risk is 10%.6 Patients with carcinoma breast showing BRCA 1 
mutation can also have a family history of ovarian carcinoma.  
Usually carcinoma breast with BRCA 1 mutations tend to be higher grade 
(grade 3) and are poorly differentiated. These carcinomas also do not express 
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estrogen receptor. BRCA 1 can also undergo sporadic type of mutation, mostly 
due to hypermethylation of promoter region. 
By using immunohistochemical studies based on the principle of directing 
antibody to the target site specific antigen, BRCA 1 expression can be studied in 
tumor cells. Normally breast tumor cells express BRCA 1 which imparts a brown 
colour when examined microscopically. Hence depending upon the intensity of 
staining in the nucleus or cytoplasm, a scoring system is devised:38 
  
score Staining of cells ( % of positive cells) 
0 No staining 
1+ < 10% positive cells 
2+ 10-25% positive cells 
3+ 25-50% positive cells 
4+ 50-70% positive cells 
5+ > 75% positive cells 
 
So 0 is considered as complete loss of BRCA 1 expression, 2 is mild 
expression, 3 is moderate expression, 4 and 5 are normal expression.38 
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Clinical significance of detecting the mutation is that the chances of 
developing carcinoma in both the breast are significantly high. Women who were 
detected positive for BRCA 1 mutation without any evidence of breast carcinoma 
can be benefited by prophylactic bilateral mastectomy were the relative risk 
reduction is around 90-100%.39 Bilateral oophorectomy can also reduce the risk of 
acquiring breast carcinoma by 47-68%.40 In a study around 49%  of cases with 
BRCA 1 mutation who underwent breast conservation surgery developed 
recurrence of carcinoma and 42% developed carcinoma in the contralateral 
breast.41 The risk of acquiring carcinoma in contralateral breast in patients with 
BRCA 1 muattion, after 10 years of follow up were 43.4%. few of the studies 
showed that usage of tamoxifen in the adjuvant therapy as a part of treatment can 
reduce the incidence of carcinoma recurrence after breast conservation surgery and 
also reduces the risk of acquiring carcinoma in the contralateral breast and there is 
a 50% reduction of contralateral carcinoma in patients who received tamoxifen as 
an part of adjuvant chemotherapy.6 
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MATERIALS AND METHODS: 
Study design and selection of study population: 
This is a retrospective study. Cases reported as carcinoma breast were 
retrieved from the archives of department of pathology, between the years 2012 to 
2015. Breast carcinomas reported in trucut biopsy and lumpectomy specimens 
were the exclusion criteria. 
Details of age of the patient, stage of the disease, radio diagnosis were 
obtained from the requisition form sent by clinicians and the details of 
pathological aspects like gross findings etc were retrieved from the archives of 
pathology. 
For histopathological examination of the tissue with breast carcinoma, 
paraffin blocks of the suitable representative section were retrieved from the 
department of pathology and they are cut to a thickness of 4 microns with the help 
of semi-automated microtome. The sections are then stained with Haematoxylin 
and Eosin manually. These slides were used for assessing the grade of the disease. 
The Haematoxylin and Eosin stained slides were examined for adequacy and as a 
rule of thumb we took a minimum of 60-70% well-preserved tumor area and 
tissues with less than 10% of necrotic area for IHC. This was done to prevent 
staining artefacts and for obtaining better results. Corresponding blocks were 
retrieved and four thin (4 to 5 microns) sections were taken to perform 
immunohistochemical study on ER, PR, HER2 and BRCA 1.  
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HAEMATOXYLIN AND EOSIN STAINING: 
Two important compositions of the stains are: 
1. Harris Haematoxylin 
2. Eosin Y 
PROCEDURE: 
With the help of microtome, 4-5 micron thin sections were floated on slides 
that are coated with egg albumin. The following staining procedure is carried as 
followed: 
1. As a first step for deparaffinization, xylene is used 
2. Section is then hydrated using graded alcohols to remove the xylene 
3. Now wash the section with water so that excess alcohol is removed 
4. Slides are then covered with Harris Haematoxylin for 10 minutes 
5. Slides are washed in running tap water for 5 minutes to remove the 
Haematoxylin, we can observe that the section gradually turn to blue and is 
called bluing. 
6. 1% acid alcohol (1% hydrochloric acid in 70% alcohol) is used to flood 
slides for 10 seconds. This is called the step of differentiation. As it 
removes the excess stain, it is also known as regressive staining. 
7. Tap water is used to wash the slides for 10 minutes 
8. Slides are then stained with eosin Y for 10 to 15 minutes 
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9. Stained slide is washed with running tap water for 3 minutes 
10. Now the sections are dehydrated using graded concentration of alcohol 
11. Xylene is the used as a clearing agent 
12. Finally DPX (distyrene phthalate xylene) is used for mounting. 
IMMUNOHISTOCHEMICAL STAINING: 
TEST PRINCIPLE: 
It is a two stage process. The first step involves the binding of the primary 
antibody to the targeted antigen in tissue tested. The second step is to identify the 
primary antibody bound to the antigen using a secondary antibody by a 
colorimetric reaction. The secondary antibody is bound to a dextran polymer with 
the help of horseradish peroxidase enzyme and an attached chromogen which is 
responsible for the production of characteristic colour. 
Immunohistochemical reagents used are: 
Antibody reagent Clone 
ER Clone EP1 by DAKO 
PR Clone PgR 636 by DAKO 
HER2 Anti-c-erbB-2 Clone CB11 by biogenex 
BRCA1 Anti-BRCA1 Protein [Polyclonal][Rabbit] 
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Retrieval of the antigen: 
When the tissue is fixed by formalin the antigenic site gets obscured. The 
masking effect is due to the formation of cross linkage. For the antibody to bind to 
the specific antigenic site, the antigen has to be exposed which are covered by the 
cross linkage. The method by which the antigenic site is made to expose so that 
the antibodies can bind freely is called as antigen retrieval.  
Few of the methods for antigen retrieval are:42 
1. Pressure cooker method 
2. Proteolytic digestion method 
3. Microwave method 
We have used the pressure cooker method for this study. It is based on the 
principle that the antigenic site can be exposed by the action of pressure and heat 
in concordance. Antigen retrieval is an important step, after dewaxing and 
hydration of the section by IHC staining procedure. Antigen retrieval by pressure 
cooker is done for 10mins in EDTA buffer at an alkaline pH of 9. 
Reagents used are: 
1. Ethylene Diamine Tetra Acetic Acid buffer at pH 9. 
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2. 3% Hydrogen Peroxide in distilled water – Is used to prevent endogenous 
peroxidase action, thereby preventing nonspecific background staining. 
3. A solution of 0.01 M Phosphate Buffered Saline (PBS) is prepared with a 
pH of 7.6. They are prepared by adding the following substance in distilled 
water. 
                       Dibasic Sodium Phosphate, Anhydrate 17.5g 
                       Monobasic Potassium Phosphate, Anhydrate 2.5g  
                       Sodium chloride 17 g 
4. Blocking: The reagent used is casein in buffered saline with 15 milli mole 
Sodium Azide, which blocks non-specific protein binding 
5. Primary antibody against BRCA 1 from Biogenex 
6. Poly HRP reagent – Horse Radish Peroxidase Enzyme 
7. DAB (3,3’DiaminoBenzdine Tetra Hydrochloride) is used the chromogen. 
This causes permanent brown precipitate. 
8. Harris Haematoxylin 
9. Distrene Dibutyl Phthalate Xylene -  for mounting 
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PROCEDURE: 
With the help of microtome, 4-5 micron thin sections were floated on slides 
that are coated with Poly L Lysine in a water bath maintained at 37 degree 
Celcius.43 The following staining procedure is carried as followed: 
1. Deparaffiniztion of slides by xylene 
2. Rehydration by graded alcohol which removes xylene 
3. Washed in running tap water for 1 minute 
4. Antigen retrieval by pressure cooker method in citrate buffer at pH 6 or 
EDTA buffer with pH 9 for 10 minutes 
5. Wash with running tap water  
6. Wash with TBS /PBS buffer at least for 5 minutes 
7. The slides are then immersed in 0.3% hydrogen peroxide for 20 minutes to 
block the non-specific background staining caused by endogenous 
peroxidase enzyme 
8. Slides are washed with PBS buffer for 5 mins 
9. Non-specific reaction of the reagent antibody with other tissue antigens is 
prevented by using a power block containing Casein and Sodium Azide. 
10. Slides are now incubated with BRCA 1 primary antibody for one hour 
11. Slides are washed with PBS buffer three times for 3 mins 
12. The sections are covered with super sensitive polymer HRP for 30 minutes 
13. Wash the slide thrice in PBS 
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14. Chromogen DAB is added and incubated for 5 to 8 minutes, were the 
colour of the section turns brown. 
15. Wash with PBS buffer three times for 5 mins and then in tap water 
16. Counter stain with Harris Hematoxylin for1 min 
17. Slides are then washed with tap water 
18. Sections are cleared with xylene and mounted with DPX. 
Blocks were also cut and stained with immunohistochemical markers for ER, PR 
and HER2, with positive controls for all three cases. 
 
The stained slides are examined for the expression of BRCA 1 and compared with 
the controls mentioned earlier. The intensity of the staining is scored arbitrarily as 
there are no established scoring systems in consideration. 
 
DATA ANALYSIS: 
Parameters that are entered in master chart are: 
Age of the patient 
Histological type of tumor 
Size of tumor 
Grade 
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TNM staging 
Nodal involvement 
Staining properties by ER, PR, HER 2 and BRCA 1. 
The information was entered into a Microsoft excel worksheet. 
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RESULTS AND OBSERVATIONS 
The department of pathology of this institute received 18,885 biopsy 
specimens over a period of January 2012 to April 2015 of which 3064 were 
reported as malignant lesions. Of these 3064 malignancies 97 were breast 
carcinomas with an incidence of 3.1%. Out of 97 cases 42 were selected for our 
study using the inclusion and exclusion criteria mentioned before. 
CHART 1: 
AGE DISTRIBUTION 
 
The above chart shows age distribution of breast carcinoma cases taken up for 
study, out of which more than half the cases are distributed between the age group 
of 40-60 years.  
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CHART 2 
HISTOLOGICAL VARIANTS OF BREAST CARCINOMA: 
 
 
The above chart shows the distribution of various histological types taken 
in our study and majority of the cases are found to be invasive ductal carcinoma, 
not otherwise specified. 
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88 
 
CHART 3 
CARCINOMA BREAST AND HISTOLOGICAL GRADING 
 
 
 
The above chart depicts that among 42 breast carcinoma cases taken for the 
study; exactly half of the cases belong to grade 2 histological type according to 
Nottingham modification of Scarff-Bloom-Richardson grading system. 
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CHART 4: 
STAGING OF BREAST CANCER 
 
 
 
The above chart shows among the 42 cases of breast cancer take up for study, 
nearly half the cases were found to be in stage II B according to the WHO TNM 
staging of breast cancer 
 
 
 
 
0
5
10
15
20
25
stageI stageIIA stageIIB stageIIIA stageIIIB stageIIIC stageIV
4
1
25
4
5
3
0
stageI
stageIIA
stageIIB
stageIIIA
stageIIIB
stageIIIC
stageIV
90 
 
TABLE 1: 
NUMBER OF BREAST CARCINOMA CASES THAT ARE ER, PR AND 
HER 2 RECEPTOR POSTVE/NEGATIVE 
 
EXPRESSION 
 
RECEPTORS 
 
The above table portrays that among the 42 cases of breast cancers taken for the 
study, almost one third of the cases are HER 2 receptor positive and half the cases 
for found to be Estrogen receptor positive 
TABLE 2 
NUMBER OF CASES WITH HISTOLOGICAL GRADING AND 
CORRELATION WITH ESTROGEN RECPETOR STATUS: 
 ER PR HER 2 
POSITIVE 20 16 29 
NEGATIVE 22 26 13 
GRADE ER POSITIVE ER NEGATIVE TOTAL NO. OF CASES 
1 7 2 9 
2 13 13 26 
3 0 7 7 
 20/42 22/42 42 
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The above table shows all the high grade tumors are ER negative and nearly all the 
low grade tumors are ER positive 
TABLE 3 
NUMBER OF CASES WITH DEGREE OF BRCA 1 EXPRESSION (MILD / 
MODERATE / STRONG / NO LOSS) 
 
DEGREE  OF  BRCA 1 EXPRESSION NUMBER OF CASES 
LOSS OF EXPRESSION 
 
0 
MILD EXPRESSION 
 
05 
MODERATE EXPRESSION 
 
03 
STRONG EXPRESSION 
 
34 
 
The above table Shows 5/42 cases of carcinoma breast with reduced BRCA 1 
expression 
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TABLE 4 
NUMBER OF CASES WITH HISTOLOGICAL GRADING AND 
CORRELATION WITH BRCA 1 EXPRESSION 
 
 
The above table shows that out of seven high grade lesions five of the cases show 
reduced BRCA 1 expression, which implies that BRCA 1 mutated lesions are of 
higher in grade. 
 
 
 
 
 
 
 
GRADE 
CASES WITH 
LOSS OF  BRCA 1 
EXPRESSION 
CASES WITH 
NORMAL BRCA 1  
EXPRESSION 
TOTAL NO. 
OF CASES 
 1 0 9 9 
2 0 26 26 
3 5 2 7 
 5/42 37/42 42 
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RESULT ANALYSIS AND DISCUSSION: 
Malignancies constituted 16.2 % among all biopsies received in the 
department of pathology of this institute and out of which 3.1 % is breast 
carcinoma. This incidence is somewhat less compared with the relative proportion 
of 26.07 % as reported in Chennai Cancer registry.52 
Invasive breast cancer is the most common malignancy in women 
accounting for 22% of all female cancers and 26% of the cancers in affluent 
society.10 This is more common in developed countries compared to that of 
underdeveloped countries 
Invasive breast carcinoma cases taken in our study belong to the age group 
21 to 80 years, with the mean age of 50.5 years (refer chart 1). Most of the studies 
involving carcinoma breast in women shows similar mean age of distribution.47 
Also the mean age of distribution is lower in developed countries compared to that 
of developing countries where there is a difference of around one decade. 
The most common histological type of carcinoma breast in our study is 
infiltrating ductal carcinoma, not otherwise specified which accounts for about 
83.3% ( refer chart 2, figure 1). The value is similar to that of the study reported in 
literature were 78.58% of cases are of the type IDC,NOS44. This justifies the fact 
that infiltrating ductal carcinoma not otherwise specified occupies the largest 
group of infiltrating breast carcinomas according to the literature.  
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Our study portrays that most of the breast carcinoma cases detected, belong 
to grade 2 which accounts for about 61.9% followed by grade 1 which accounts 
for about 21.42% and grade 3 which accounts for about 16.66% (refer table 3) 
which is comparatively similar to that of the study conducted by Madhu Batra et al 
which reported the percentage of cases with grade 1 lesion as 15%, grade 2 lesion 
as 57.5% and grade 3 lesion as 27.5%.45 Our study also highlighted that Stage II 
breast cancer accounts for about 61.9% of cases which is similar to the data 
obtained from a study which reported majority of the carcinoma breast cases (23-
58%) belong to stage II lesion.46( refer table 4).  
Out of 42 cases taken in our study estrogen receptor was positive for 20 
cases (47.61%) and negative for 22 cases (52.38%)(refer table 5, figure 4).  The 
estrogen receptor positivity is quite high by 10% compared to that of the study 
reported in literature which showed only 35% of cases were estrogen receptor 
positive.44,47 All high grade lesions are estrogen receptor negative (7/7) (100%) 
(Refer table 6). Out of these seven cases five cases showed loss of BRCA 1 
expression which is significant.  
Out of 42 cases HER 2 receptor was positive in 29 cases (69.04%) and 
progesterone receptor was positive in 16 cases (38.09%)( refer table 5, figure 
5&6). They didn’t show any correlation with grading or BRCA 1 expression 
which is similar to the study reported in literature.48 HER 2 receptor expression is 
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high compared to that of study reported in literature and significantly high in 
comparison with the international values of 20-30%.49 (refer table 5) 
BRCA 1 a tumor suppressor gene when mutated can cause carcinoma 
breast, most of the mutations are germline mutations that are hereditary in 
preposition, whereas few of the cases can also have sporadic mutation due to 
hypermethylation of promotor region in BRCA 1gene. Germline mutation confers 
an estimated cumulative risk of breast cancer around 50% until age of 5 years.50 
BRCA 1 mutated tumors are tumors of high grade and lack the expression 
of hormonal receptors. They can be aggressive tumors showing marked variation 
in histopathological features and thus influencing the prognosis of patients 
Loss of BRCA 1 expression is considered in our study population when the 
cells show mild positivity for BRCA 1. Out of 42 cases 5 cases show loss of 
BRCA 1 expression which accounts for 11.9% (refer table 7, figure 7) which is in 
concordance with the study reported in literature.45 Also among the high grade 
lesions (7 cases with grade 3 carcinoma), reduced BRCA 1 expression accounts 
for about 71.42% (5/7)( refer table 8). The value is similar to that of the study 
conducted by Fahd Al-Mulla et al, which reported that 77% of their cases with 
high grade lesion (grade 3) show reduced BRCA 1 expression.51Low expression of 
BRCA 1 is considered significant in our study, as the five cases which showed 
loss BRCA 1 expression were high grade tumors (grade 3) and were negative for 
estrogen receptor, which is similar to that reported in literature.6 
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SUMMARY AND CONCLUSION: 
In conclusion, our study on breast carcinoma specimen revealed the 
incidence is around 3.1% of breast cancer among women. Majority of which 
occurs in the mean age group of 50.5 years. We infer that BRCA 1 mutation was 
seen mostly in grade 3 / high grade tumors. BRCA 1 mutation was also seen in 
hormone receptor negative cases, in particular estrogen receptors. The limitations 
of our study include small sample size. A larger prospective study on the utility of 
BRCA 1 immunohistochemistry is essential to prove the benefits of this mutation 
analysis for routine treatment and prognostic reasons. 
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S.NO SLIDE NO AGE/SEX Histological type of tumor 
size-
cm 
No. of 
nodes Grade 
TNM 
Staging Staging ER PR HER 2  
BRCA 1 
Expression 
1 4265/12 47/F Infiltarting ductal ca, NOS 3.5 0/11 2 T2N0M0 II A NEGATIVE  NEGATIVE  POSITIVE STRONG 
2 4049/12 51/F IDC, NOS 3.7 0/7 3 T2N0M0 II A NEGATIVE  NEGATIVE  POSITIVE LOSS 
3 1187/13 47/F IDC, NOS 16 0/20 3 T4N0M0 III B NEGATIVE  NEGATIVE  POSITIVE STRONG 
4 2000/13 60/F IDC, NOS 2 1 of 8 2 T1CN1M0 II A POSITIVE POSITIVE POSITIVE STRONG 
5 2166/13 42/F IDC, NOS 4 0/15 3 T2N0M0 II A NEGATIVE  NEGATIVE  POSITIVE LOSS 
6 3262/13 68/F IDC, NOS 4.5 0/7 1 T2N0M0 II A POSITIVE POSITIVE POSITIVE STRONG 
7 4310/13 58/F IDC, NOS 2 0/11 1 T1CN0M0 IA NEGATIVE  NEGATIVE  POSITIVE STRONG 
8 4614/13 65/F IDC, NOS 4 6 of 18 2 T2N2M0 IIIA NEGATIVE  NEGATIVE  POSITIVE STRONG 
9 5324/13 32/F IDC, NOS 6 0/16 2 T3N0M0 IIB POSITIVE POSITIVE POSITIVE STRONG 
10 3600/13 52/F IDC, NOS 9 11 of 19 3 T3N3M0 IIIC NEGATIVE  NEGATIVE  POSITIVE STRONG 
11 3704/13 40/F IDC, NOS 4 1 of 11 2 T2N1M0 IIB NEGATIVE  NEGATIVE  NEGATIVE  STRONG 
12 3415/14 55/F IDC, NOS 3 0/27 3 T2N0M0 IIA NEGATIVE  NEGATIVE  POSITIVE MODERATE 
13 533/14 53/F IDC, NOS 7.5 1 of 19 2 T3N1M0 IIIA NEGATIVE  NEGATIVE  NEGATIVE  STRONG 
14 135/14 65/F Invasive Lobular Carcinoma 3.5 0/12 2 T2N0M0 IIA NEGATIVE  NEGATIVE  POSITIVE STRONG 
15 2363/14 62/F IDC, NOS 8 0/17 2 T3N0M0 IIB POSITIVE POSITIVE NEGATIVE  STRONG 
16 1535/14 75/F Invasive Apocrine Carcinoma 4 0/9 2 T2N0M0 IIA NEGATIVE  NEGATIVE  POSITIVE STRONG 
17 1159/14 38/F Invasive Apocrine Carcinoma 3.5 0/15 2 T2N0M0 IIA POSITIVE POSITIVE POSITIVE MODERATE 
18 4896/14 45/F IDC, NOS 2.5 0/15 2 T2N0M0 IIA POSITIVE POSITIVE POSITIVE STRONG 
19 4736/14 52/F IDC, NOS 2 0/7 3 T4N2M0 IIIB NEGATIVE  NEGATIVE  NEGATIVE  LOSS 
20 4293/14 60/F IDC, NOS 3.5 0/11 2 T1CN0M0 IA POSITIVE POSITIVE POSITIVE STRONG 
21 393/14 42/F IDC, NOS 2 0/25 1 T2N0M0 IIA POSITIVE POSITIVE POSITIVE STRONG 
22 4036/14 74/F Mucinous Carcinoma 9 0/9 1 T1CN0M0 IA NEGATIVE  NEGATIVE  NEGATIVE  STRONG 
23 2958/14 63/F 
IDC AND Mucinous 
carcinoma 8 5 of 13 2 T3N1M0 IIIA POSITIVE POSITIVE NEGATIVE  STRONG 
24 5069/14 77/F IDC, NOS 3.5     1 of 10 1 T2N1M0 IIB POSITIVE POSITIVE NEGATIVE  STRONG 
25 627/15 34/F IDC, NOS 2.5 13 of 30 2 T2N3M0 IIIC NEGATIVE  NEGATIVE  NEGATIVE  STRONG 
26 932/15 50/F IDC, NOS 3 1 of 15 2 T3N1M0 IIIA POSITIVE NEGATIVE  POSITIVE STRONG 
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27 4170/12 62/F IDC, NOS 4.5 0/31 2 T3N0M0 IIB NEGATIVE  NEGATIVE  POSITIVE STRONG 
28 4116/12 53/F IDC, NOS 5 1 of 17 1 T2N1M0 IIB POSITIVE POSITIVE POSITIVE STRONG 
29 2577/12 40/F IDC, NOS 2.5 8 of 25 2 T1N2M0 IIIA POSITIVE POSITIVE POSITIVE STRONG 
30 3675/13 64/F IDC, NOS 1 5 of 10 2 T1bN2M0 IIIA POSITIVE POSITIVE POSITIVE MODERATE 
31 3279/12 66/F Invasive Papillary Carcinoma 5 0/13 1 T2N0M0 IIA NEGATIVE  NEGATIVE  POSITIVE STRONG 
32 4254/14 68/F IDC With Apocrine changes 3 25 of 32 2 T2N3M0 IIIC NEGATIVE  NEGATIVE  NEGATIVE  STRONG 
 
33 3840/13 47/F IDC, NOS 3 1 of 19 2 T2N1M0 IIB POSITIVE POSITIVE POSITIVE STRONG 
34 1016/14 48/F IDC, NOS 3.5 3 of 22 3 T2N1M0 IIB NEGATIVE  NEGATIVE  POSITIVE STRONG 
35 4013/14 56/F IDC, NOS 2.5 0/23 3 T2N0M0 IIA NEGATIVE  NEGATIVE  POSITIVE LOSS 
36 1012/13 47/F IDC, NOS 2.5 6 of 15 2 T2N0M0 IIA POSITIVE POSITIVE POSITIVE STRONG 
37 2708/12 44/7 IDC, NOS 2 0/16 2 T1cN0M0 IIA NEGATIVE  NEGATIVE  POSITIVE STRONG 
38 807/12 48/F IDC, NOS 2.5 0/19 2 T2N0M0 IIA POSITIVE POSITIVE NEGATIVE  STRONG 
39 5650/14 45/F IDC, NOS 4.5 1 of 13 2 T2N1M0 IIB POSITIVE POSITIVE NEGATIVE  STRONG 
40 325/14 33/F IDC, NOS 2 0/11 1 T1cN0M0 IIA POSITIVE NEGATIVE  NEGATIVE  STRONG 
41 3415/14 55/F IDC, NOS 3 0/8 3 T2N0M0 IIA NEGATIVE  NEGATIVE  POSITIVE LOSS 
42 2362/14 62/F IDC, NOS 8 0/13 2 T3N0M0 IIB POSITIVE POSITIVE POSITIVE STRONG 
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